Bas Groot Koerkamp (@BasGrootKoerkam) profile picture

HPB-transplant surgeon

Rotterdam, the Netherlands
Joined April 2013
Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)Photo by Bas Groot Koerkamp (@BasGrootKoerkam)
Bas Groot Koerkamp retweeted
🔥off the press🔥 Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study doi.org/10.1016/j.cgh.2026.0… 👉408 pts 👉Tumor burden & AFP at LT associated with HCC recurrence 👉Rejection associated with non-HBV, irAEs, age, shorter ICI washout 🧐pre-LT ICI feasible, clinical utility needs to be established @myESMO @EASLnews @ILCAnews
1
33
2
65
4,844
Bas Groot Koerkamp retweeted
Privilege of the podium in Singapore with legends in HPB Surgery! @IHPBA @BasGrootKoerkam @MonicaDuaMD @ElenaPanettier1 @MedStarGUH @MedStarWHC @MedStarHealth @LombardiCancer
1
4
23
1,084
Bas Groot Koerkamp retweeted
Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE ➡️mPFS 14.6 v 10.2 HR 0.7 ➡️ORR 71 v 49% by mRECIST ❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx ❎much higher gd3/4 TRAEs 71%v31% ➡️❗️1/3 BCLCA ➡️Role combo unclear consistent -ve OS @myESMO #ESMO26 @OncoAlert
13
22
1,102
Bas Groot Koerkamp retweeted
Replying to @SaborowskiAnna
@SaborowskiAnna putting into the context abstracts on #HCC from intermediate to advanced stage, from #TACE+immunotherapy to #CAR-T at #ESMO26 #ESMOAmbassadors @myESMO
4
9
396
Bas Groot Koerkamp retweeted
Congrats to Dr. @vikram_chaudhari for leading the Delphi consensus process for gallbladder classification at @IHPBA . Honored to participate. @Shrikhande_SV @TataMemorial
15
1
70
4,003
Bas Groot Koerkamp retweeted
HRS-4642 plus CTx ± adebrelimab as perioperative therapy in KRAS G12D-mPDAC: Preliminary results of a phase 2 study #ESMO26 #ESMOAmbassadors 👉ORR: 63 vs 87% 👉Manageable safety 🧐 exciting results, tumor shrinkage in all pts, added benefit of ICI remains to be seen @myESMO @ASCO
12
1
20
1,401
Bas Groot Koerkamp retweeted
Lots of hard work moving this project forward - SAFIR-IMPACT-BTC 📸Meeting at @myESMO #ESMO26 Delighted to see how #AcademicResearch brings people together 😊We are a very close and collaborative research community, working together to improve outcomes in #BiliaryMalignancies
🔔Great news! #Funded projects #ATTRACT2025 𝗦𝗔𝗙𝗜𝗥 𝗜𝗠𝗣𝗔𝗖𝗧 𝗕𝗧𝗖 - PhIII - Precision Medicine Adjuvant #BiliaryMalignancies 𝗖𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗼𝗿: #JulienEdeline 𝗖𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺: 🇫🇷🇪🇸🇧🇪🇳🇱 Spain. Led by 🙋🏻‍♀️, @Hospital_FJD @GrupoTTD @ContraCancerEs
4
11
604
Tomorrow at #ESMO26: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success. 🗓️ Monday, October 26 | 11:15 a.m. CET
1
7
1
33
2,228
Bas Groot Koerkamp retweeted
Masterful talk @BasGrootKoerkam on localised #PDAC & #BTC 🔑points👇 ➡️PDAC staging requires anatomy/biology/clinical ass ➡️?older patients benefit NAC ➡️hilar obs➡️perc stenting TESLA ➡️high risk iCCA consider NAC ➡️LRT & Liver tx evolving in iCCA @myESMO #ESMO26 @OncoAlert
18
1
48
5,009
Bas Groot Koerkamp retweeted
🔬Ivonescimab now represent a promising emerging therapeutic option - exciting progress for cholangiocarcinoma and biliary tract cancer patients @curecc
HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies ✅OS HR 0.75, mOS 12.1vs14.9 ✅PFS HR 0.61, mPFS 6.8vs8.4 ✅ORR 53.8vs32.5 🌐China only BUT 😊This is a positive trial 🥳VEGF is back #ESMOAmbassadors
5
7
347
Bas Groot Koerkamp retweeted
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology @Annals_Oncology doi.org/10.1016/j.annonc.202… 👉helpful for interpreting actionability and decision making @myESMO @ASCO
1
10
15
1,526
Which approach offers safer biliary drainage? See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
5
6
641
Bas Groot Koerkamp retweeted
Video-based assessment identified a learning curve of approximately 34 robotic gastroenterostomies during pancreatoduodenectomy, with rates of clinically relevant delayed gastric emptying declining from 25.7% to 11.5% after the learning curve. ovid.com/10.1097/SLA.0000000…
4
11
1,786
Bas Groot Koerkamp retweeted
The TESLA trial - my highlight at today’s late breaking abstract session at #UEGWeek Question: For malignant hilar obstruction, which is better: percutaneous drainage (PTC) or endoscopic drainage (ERCP)? Result: PTC > ERCP for unresectable hilar strictures.
4
28
2
114
14,326
Bas Groot Koerkamp retweeted
What is the optimal duration of antibiotics after ERCP decompression for cholangitis? The #UEGWeek 2026 top abstract prize goes to Anouk Overdevest for her work on the COBRA trial, which shows that 1 day of antibiotic is non-inferior to 4-7 day courses 👏🏆
🤖 Made with AI
6
87
5
263
18,808
Bas Groot Koerkamp retweeted
5 Pancreatic Cancer Trials to Watch at ESMO 2026 The ESMO Congress 2026 will feature new pancreatic cancer data across resected, borderline resectable, locally advanced, and metastatic disease. Trials to watch: • RASolute 302 — Additional subgroup analyses of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma • AMPLIFY-7P — Randomized phase II results with ELI-002 7P vs observation in resected pancreatic ductal adenocarcinoma • MASTERPLAN — mFOLFIRINOX with or without SBRT in patients with high-risk, borderline resectable, or locally advanced pancreatic cancer • HRS-4642 — Preliminary phase II results with HRS-4642 + chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer • INCB161734 — Safety and efficacy of INCB161734 in combination with chemotherapy in advanced or metastatic pancreatic ductal adenocarcinoma Together, these five presentations will provide additional data across resected, locally advanced, and metastatic pancreatic cancer, including several RAS-directed treatment strategies. @AHollebecque @WainbergZev @EileenMOReilly 📎oncodaily.com/gastrointestin… #ESMO2026 #KRAS #OncoDaily
11
21
1,161
Bas Groot Koerkamp retweeted
🔥off the press🔥 Overall and Line-Specific Impact of Targeted Therapies in Advanced BTC After Chemoimmunotherapy Failure @JHepatology doi.org/10.1016/j.jhep.2026.… 👉continuous evidence for 🎯💊in BTC 🧐we need to make sure that these therapies are accessible to all (!) patients @myESMO @ASCOPost @EASLedu @ILCAnews
2
35
51
3,509
Bas Groot Koerkamp retweeted
📝 #JAMAReview: #LiquidBiopsy using circulating #tumor #DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy. Detectable circulating tumor DNA after curative-intent treatment was associated with recurrence and poorer survival across multiple cancer settings, often before progression was evident on imaging. ja.ma/4dFgtVU
9
130
6
391
26,214
The use of locoregional therapies in cholangiocarcinoma - JHep Oct 2026 sciencedirect.com/science/ar… @curecc @CharityAMMF @EASLnews @ENS_CCA
3
19
2,202